Animal Gastroesophageal Reflux Disease Market Projected to Reach $2.9 Billion by 2030 at 8.5% CAGR
The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
How Much Is The Active Pharmaceutical Ingredients Market Expected To Grow In Terms Of Market Value Between 2026 And 2030?
The animal gastroesophageal reflux disease market has shown robust expansion in recent years. Its value is expected to increase from $1.98 billion in 2025 to $2.16 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.8%. The growth observed in prior periods is attributable to factors including limited awareness of animal GERD among veterinarians, a high prevalence of GERD in companion animals, a shortage of advanced diagnostics in veterinary hospitals, a reliance on generic medications, and the increasing number of veterinary clinics and hospitals.
The market for animal gastroesophageal reflux disease is projected to experience substantial growth over the coming years, reaching $2.99 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.5%. This anticipated expansion throughout the forecast period is driven by factors such as the advancement of diagnostic methods like endoscopy and manometry, a heightened emphasis on nutritional and dietary management, increased uptake of both over-the-counter and prescription medications, the broadening reach of veterinary e-commerce, and the incorporation of AI and digital platforms to deliver tailored treatments. Key trends expected during this period involve a greater acceptance of endoscopy and pH monitoring for GERD diagnosis, an increase in the application of nutritional supplements and dietary adjustments in patient management, enhanced availability of prescription and OTC drugs for pets, the proliferation of minimally invasive surgical options for GERD therapy, and the development of personalized treatment plans for both livestock and companion animals.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20464&type=smp
What Drivers Are Influencing The Active Pharmaceutical Ingredients Market?
The increasing humanization of pets is anticipated to drive the expansion of the animal gastroesophageal reflux disease market. This trend involves pet owners treating their animals as akin to human family members, attributing human emotions, requirements, and behaviors to them. The growing emotional connections between owners and their pets fuel this humanization, leading to a heightened need for specialized healthcare, high-quality diets, and wellness products that align with human expectations. Furthermore, the humanization of pets raises awareness of conditions such as gastroesophageal reflux disease (GERD), prompting more vigilant owners to seek veterinary attention and thereby boosting demand for diagnostic tools, treatments, and preventive measures. For example, in April 2024, data from the American Pet Products Association, a US-based not-for-profit industry association, indicated that 86.9 million households in the US owned a pet in 2023-2024, representing 66% of households, an increase from 62% in 2022. Thus, the increasing humanization of pets is a key factor propelling the growth of the animal gastroesophageal reflux disease market.
What Major Segment Divisions Exist Within The Active Pharmaceutical Ingredients Market?
The animal gastroesophageal reflux disease market covered in this report is segmented –
1) By Product: Treatment, Diagnostics
2) By Mode: Over-The-Counter (OTC), Prescription
3) By Route Of Administration: Oral, Injectable
4) By Animal: Companion Animals, Livestock Animal
5) By Distribution Channel: Veterinary Hospitals And Clinics, Retail Pharmacies, E-Commerce
Subsegments:
1) By Treatment: Medications, Surgical Interventions, Dietary Modifications, Nutritional Supplements, Antacids
2) By Diagnostics: Endoscopy, Esophageal pH Monitoring, Manometry, Ultrasound, Radiographic Studies, Biopsy Techniques
How Are Trends Shaping The Direction Of The Animal Gastroesophageal Reflux Disease Market?
Leading companies in the animal gastroesophageal reflux disease market are developing specialized diets to support gastrointestinal health, thereby improving digestive function and managing GERD symptoms in pets. Gastrointestinal support diets represent specifically formulated pet foods designed to alleviate and control the manifestations of gastrointestinal disorders. These dietary solutions typically incorporate easily digestible components, balanced nutritional profiles, and added fibers or probiotics to foster digestive well-being and overall health. For example, in April 2024, Royal Canin, a USA-based subsidiary of Mars Incorporated and a producer of cat and dog food, expanded its veterinary gastrointestinal (GI) portfolio by introducing five new diets aimed at enhancing the gastrointestinal health of pets. These specialized diets, developed in collaboration with researchers, veterinarians, and specialists, are focused on addressing GI issues in both dogs and cats, including food-responsive sensitivities and fat-restricted requirements. The new products feature options such as gastrointestinal low-fat, hydrolyzed protein canine, and gastrointestinal hydrolyzed protein feline, all meticulously formulated with highly digestible ingredients to promote long-term gastrointestinal health.
Which Companies Are Leading Innovation In The Active Pharmaceutical Ingredients Market?
Major companies operating in the animal gastroesophageal reflux disease market are Zoetis Inc., VCA Animal Hospitals, Petco Health and Wellness Company Inc., Merck Animal Health, Boehringer Ingelheim Animal Health, Elanco Animal Health Incorporated, Hill’s Pet Nutrition Inc., IDEXX Laboratories Inc., Ceva Santé Animale, Virbac S.A., Phibro Animal Health Corporation, Dechra Pharmaceuticals PLC, Blue Buffalo Company Ltd., Vetoquinol S.A., Antech Diagnostics, Heska Corporation, WellPet LLC, McNeil Consumer Pharmaceuticals Co., Wag Labs Inc. , VetPartners Limited, BioZyme Inc., Zomedica Corp., NexGen Pharmaceuticals LLC
Read the full animal gastroesophageal reflux disease market report here:
Which Regions Are Expected To Experience Rapid Expansion In The Active Pharmaceutical Ingredients Market?
North America was the largest region in the animal gastroesophageal reflux disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the animal gastroesophageal reflux disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Active Pharmaceutical Ingredients Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=20464&type=smp
Browse Through More Reports Similar to the Global Animal Gastroesophageal Reflux Disease Market 2026, By The Business Research Company
Gastroesophageal Reflux Disease Therapeutics Global Market Report 2026
Animal Therapeutics And Diagnostics Global Market Report 2026
Animal Biotechnology Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/animal-biotechnology-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
